v3.26.1
Non-Controlling Interests - Summary of Financial Information (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
 [1]
Disclosure of subsidiaries [line items]        
Non-current assets € 14,638 € 15,677    
Current assets 5,074 5,728    
Non-current liabilities (10,090) (10,643)    
Current liabilities (2,019) (2,156)    
Equity 7,603 8,606 [1] € 7,513 [1] € 7,977
Non-controlling interests 2,332 2,723    
Net revenue 7,524 7,212 6,592 [1]  
Consolidated net profit 500 213 163 [1]  
Consolidated net income 98 56 121 [1]  
Total        
Disclosure of subsidiaries [line items]        
Non-current assets 6,836 7,227    
Current assets 1,206 1,180    
Non-current liabilities (927) (995)    
Current liabilities (1,058) (863)    
Total Consolidated Equity (except for intercompany eliminations) 5,324 5,889    
Non-controlling interests 2,310 2,706    
Net revenue 1,689 1,732    
Consolidated net profit 118 60    
Consolidated net income € 95 € 53    
Biotest AG        
Disclosure of subsidiaries [line items]        
% Non-controlling Interest 19.60% 29.80%    
Non-controlling interests € 204 € 330    
Consolidated net income (18) (29)    
Biotest AG | Biotest AG        
Disclosure of subsidiaries [line items]        
Non-current assets 2,195 2,130    
Current assets 876 780    
Non-current liabilities (487) (540)    
Current liabilities (854) (657)    
Total Consolidated Equity (except for intercompany eliminations) 1,041 1,105    
Net revenue 675 726    
Consolidated net profit € (72) € (96)    
GDS Group        
Disclosure of subsidiaries [line items]        
% Non-controlling Interest 45.00% 45.00%    
Non-controlling interests € 1,781 € 1,970    
Consolidated net income 62 48    
GDS Group | GDS Group        
Disclosure of subsidiaries [line items]        
Non-current assets 4,197 4,627    
Current assets 251 253    
Non-current liabilities (349) (368)    
Current liabilities (141) (134)    
Total Consolidated Equity (except for intercompany eliminations) 3,958 4,378    
Net revenue 571 578    
Consolidated net profit € 139 € 122    
Haema AG        
Disclosure of subsidiaries [line items]        
% Non-controlling Interest 100.00% 100.00%    
Non-controlling interests € 184 € 260    
Consolidated net income 11 6    
Haema AG | Haema AG        
Disclosure of subsidiaries [line items]        
Non-current assets 239 230    
Current assets 46 121    
Non-current liabilities (46) (34)    
Current liabilities (41) (50)    
Total Consolidated Equity (except for intercompany eliminations) 184 260    
Net revenue 219 204    
Consolidated net profit € 11 € 6    
BPC Plasma, Inc        
Disclosure of subsidiaries [line items]        
% Non-controlling Interest 100.00% 100.00%    
Non-controlling interests € 141 € 146    
Consolidated net income 40 28    
BPC Plasma, Inc | BPC Plasma, Inc        
Disclosure of subsidiaries [line items]        
Non-current assets 205 240    
Current assets 33 26    
Non-current liabilities (45) (53)    
Current liabilities (22) (22)    
Total Consolidated Equity (except for intercompany eliminations) 141 146    
Net revenue 224 224    
Consolidated net profit 40 28    
Non-controlling interests        
Disclosure of subsidiaries [line items]        
Equity 2,332 2,723 [1] 2,145 [1] € 2,328
Consolidated net profit 98 56    
Non-controlling interests | Biotest AG        
Disclosure of subsidiaries [line items]        
Equity 204 330 357  
Consolidated net profit (18) (29)    
Non-controlling interests | BPC Plasma, Inc        
Disclosure of subsidiaries [line items]        
Equity 141 146 € 148  
Consolidated net profit € 40 € 28    
[1] (See Note 2.d)